Guangzhou Baiyunshan Pharmaceutical Holdings (00874): Tianxin Pharmaceutical has received the "Official Drug Registration Certificate" issued by the Macau Health Bureau.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its holding subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings Tianxin Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianxin Pharmaceutical"), recently received a "Drug Registration Certificate" issued by the Macao Special Administrative Region Government's Drug Supervision Administration. Tianxin Pharmaceutical submitted a drug registration application for Cefazolin Sodium for Injection (0.5g, 1.0g) to the Macao Special Administrative Region Government's Drug Supervision Administration on June 22, 2026, and obtained preliminary permission for acceptance on July 31, 2026. Cefazolin Sodium for Injection is indicated for the treatment of respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infectious endocarditis, hepatobiliary infections, reproductive system infections, and for the prevention of perioperative infections caused by sensitive bacteria. This product is not suitable for treating central nervous system infections. Its efficacy is poor for chronic urinary tract infections, especially those accompanied by anatomical abnormalities of the urinary tract. This product is not suitable for the treatment of gonorrhea and syphilis. According to data from Meini Network, the sales revenue of Cefazolin Sodium for Injection in public hospitals at the urban and county levels, as well as urban and online pharmacies, was 824.81 million RMB in 2025. Currently, major manufacturers of Cefazolin Sodium for Injection in China include Qilu Anti-Pharmaceutical Co., Ltd., Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd., and Chengdu Beta Pharmaceutical Co., Ltd. The sales revenue of Tianxin Pharmaceutical's Cefazolin Sodium for Injection in 2025 was 715,800 RMB. As of the date of this announcement, Tianxin Pharmaceutical has accumulated approximately 6.1086 million RMB (unaudited) in research and development expenses for the Cefazolin Sodium for Injection project.